ID

34714

Description

Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist; ODM derived from: https://clinicaltrials.gov/show/NCT01381926

Lien

https://clinicaltrials.gov/show/NCT01381926

Mots-clés

Versions (1)
  1. 24/01/2019 24/01/2019 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

24 janvier 2019

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Type 2 Diabetes Mellitus NCT01381926

Anglais

Eligibility Type 2 Diabetes Mellitus NCT01381926

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
postmenopausal women (as defined by age ≥45 years old or amenorrhea for >2years)
Description

Postmenopausal state | Age | Amenorrhea Duration

Type de données

boolean

Alias
UMLS CUI [1]
C0232970
UMLS CUI [2]
C0001779
UMLS CUI [3,1]
C0002453
UMLS CUI [3,2]
C0449238
type 2 dm currently not on diabetes-specific medication(s) or treated with monotherapy of metformin or a sulfonylurea. patients treated with insulin monotherapy will also be eligible if the total daily dose of insulin is ≤10units. if on a medication for diabetes prior to study entry, the medication can be discontinued for 2 weeks prior to study initiation.
Description

Diabetes Mellitus, Non-Insulin-Dependent | Antidiabetics Absent | Metformin | Sulfonylurea | Insulin regime U/day

Type de données

boolean

Alias
UMLS CUI [1]
C0011860
UMLS CUI [2,1]
C0935929
UMLS CUI [2,2]
C0332197
UMLS CUI [3]
C0025598
UMLS CUI [4]
C0038766
UMLS CUI [5,1]
C0557978
UMLS CUI [5,2]
C0456683
hemoglobin a1c (hba1c) of 6.5-9.0%
Description

Hemoglobin A1c measurement

Type de données

boolean

Alias
UMLS CUI [1]
C0474680
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
use of an incretin mimetic (i.e. exenatide, liraglutide), a dpp-4 inhibitor (i.e. sitagliptin, saxagliptin), a thiazolidinedione, or oral glucocorticoids in the 6 months prior to the study will not be eligible
Description

Incretin mimetic product | exenatide | liraglutide | Dipeptidyl-Peptidase IV Inhibitors | sitagliptin | saxagliptin | Thiazolidinediones | Glucocorticoids Oral

Type de données

boolean

Alias
UMLS CUI [1]
C1562104
UMLS CUI [2]
C0167117
UMLS CUI [3]
C1456408
UMLS CUI [4]
C1827106
UMLS CUI [5]
C1565750
UMLS CUI [6]
C1611934
UMLS CUI [7]
C1257987
UMLS CUI [8,1]
C0017710
UMLS CUI [8,2]
C1527415
known osteoporosis or patients treated with an osteoporosis-specific medication (bisphosphonate, teriparatide) or estrogen (including selective estrogen receptor modulators (serms)) or those who anticipate imminent treatment with one of these medications will be excluded from the study
Description

Osteoporosis | Pharmaceutical Preparations Osteoporosis Specific | Diphosphonates | Teriparatide | Estrogens | Selective Estrogen Receptor Modulators

Type de données

boolean

Alias
UMLS CUI [1]
C0029456
UMLS CUI [2,1]
C0013227
UMLS CUI [2,2]
C0029456
UMLS CUI [2,3]
C0205369
UMLS CUI [3]
C0012544
UMLS CUI [4]
C0070093
UMLS CUI [5]
C0014939
UMLS CUI [6]
C0732611
chronic kidney disease (calculated gfr <30 ml/min) or a disease known to affect bone turnover (i.e. paget disease, osteogenesis imperfecta, hiv) will be excluded from the study.
Description

Chronic Kidney Disease | Glomerular Filtration Rate | Disease Affecting Bone remodeling | Paget's disease | Osteogenesis Imperfecta | HIV Infection

Type de données

boolean

Alias
UMLS CUI [1]
C1561643
UMLS CUI [2]
C0017654
UMLS CUI [3,1]
C0012634
UMLS CUI [3,2]
C0392760
UMLS CUI [3,3]
C0085268
UMLS CUI [4]
C0029401
UMLS CUI [5]
C0029434
UMLS CUI [6]
C0019693
history of pancreatitis
Description

Pancreatitis

Type de données

boolean

Alias
UMLS CUI [1]
C0030305
Retour au début de la page

Similar models

Eligibility Type 2 Diabetes Mellitus NCT01381926

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Postmenopausal state | Age | Amenorrhea Duration
Item
postmenopausal women (as defined by age ≥45 years old or amenorrhea for >2years)
boolean
C0232970 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0002453 (UMLS CUI [3,1])
C0449238 (UMLS CUI [3,2])
Diabetes Mellitus, Non-Insulin-Dependent | Antidiabetics Absent | Metformin | Sulfonylurea | Insulin regime U/day
Item
type 2 dm currently not on diabetes-specific medication(s) or treated with monotherapy of metformin or a sulfonylurea. patients treated with insulin monotherapy will also be eligible if the total daily dose of insulin is ≤10units. if on a medication for diabetes prior to study entry, the medication can be discontinued for 2 weeks prior to study initiation.
boolean
C0011860 (UMLS CUI [1])
C0935929 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0025598 (UMLS CUI [3])
C0038766 (UMLS CUI [4])
C0557978 (UMLS CUI [5,1])
C0456683 (UMLS CUI [5,2])
Hemoglobin A1c measurement
Item
hemoglobin a1c (hba1c) of 6.5-9.0%
boolean
C0474680 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Incretin mimetic product | exenatide | liraglutide | Dipeptidyl-Peptidase IV Inhibitors | sitagliptin | saxagliptin | Thiazolidinediones | Glucocorticoids Oral
Item
use of an incretin mimetic (i.e. exenatide, liraglutide), a dpp-4 inhibitor (i.e. sitagliptin, saxagliptin), a thiazolidinedione, or oral glucocorticoids in the 6 months prior to the study will not be eligible
boolean
C1562104 (UMLS CUI [1])
C0167117 (UMLS CUI [2])
C1456408 (UMLS CUI [3])
C1827106 (UMLS CUI [4])
C1565750 (UMLS CUI [5])
C1611934 (UMLS CUI [6])
C1257987 (UMLS CUI [7])
C0017710 (UMLS CUI [8,1])
C1527415 (UMLS CUI [8,2])
Osteoporosis | Pharmaceutical Preparations Osteoporosis Specific | Diphosphonates | Teriparatide | Estrogens | Selective Estrogen Receptor Modulators
Item
known osteoporosis or patients treated with an osteoporosis-specific medication (bisphosphonate, teriparatide) or estrogen (including selective estrogen receptor modulators (serms)) or those who anticipate imminent treatment with one of these medications will be excluded from the study
boolean
C0029456 (UMLS CUI [1])
C0013227 (UMLS CUI [2,1])
C0029456 (UMLS CUI [2,2])
C0205369 (UMLS CUI [2,3])
C0012544 (UMLS CUI [3])
C0070093 (UMLS CUI [4])
C0014939 (UMLS CUI [5])
C0732611 (UMLS CUI [6])
Chronic Kidney Disease | Glomerular Filtration Rate | Disease Affecting Bone remodeling | Paget's disease | Osteogenesis Imperfecta | HIV Infection
Item
chronic kidney disease (calculated gfr <30 ml/min) or a disease known to affect bone turnover (i.e. paget disease, osteogenesis imperfecta, hiv) will be excluded from the study.
boolean
C1561643 (UMLS CUI [1])
C0017654 (UMLS CUI [2])
C0012634 (UMLS CUI [3,1])
C0392760 (UMLS CUI [3,2])
C0085268 (UMLS CUI [3,3])
C0029401 (UMLS CUI [4])
C0029434 (UMLS CUI [5])
C0019693 (UMLS CUI [6])
Pancreatitis
Item
history of pancreatitis
boolean
C0030305 (UMLS CUI [1])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial